SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today announced it will present
at the upcoming H.C. Wainwright Global Life Sciences
Conference. Evofem's CEO, Saundra
Pelletier, will provide an update on the commercialization
of its non-hormonal, use-it-only-when-you-need-it birth control
method, Phexxi® (lactic acid, citric acid and potassium
bitartrate) vaginal gel.
The presentation will be available for on-demand listening
beginning Tuesday, March 9,
2021, at 7:00 a.m. ET on the
Investors section of the Company's website at www.evofem.com,
under the Events and Presentations tab; click here for direct access.
On Valentine's Day, the Company launched "Get Phexxi", a
national direct-to-consumer (DTC) campaign aimed at broadening
Phexxi's awareness. Click here to view the "Get Phexxi"
commercial on demand.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a commercial-stage biopharmaceutical company
committed to developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health. The
Company's first commercial product, Phexxi®, is the first and only
hormone-free, prescription vaginal gel approved in the United
States for the prevention of pregnancy. The Company's lead
product candidate, EVO100, is being evaluated for the prevention of
urogenital Chlamydia trachomatis and Neisseria
gonorrhoeae infection in women in the ongoing Phase 3
clinical trial, 'EVOGUARD'. For more information, please
visit www.evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-hc-wainwright-global-life-sciences-conference-301232996.html
SOURCE Evofem Biosciences, Inc.